Influenza and Other Respiratory Virus Weekly Activity Report, April 18, 2009, Week 15

Weekly report of the Iowa Influenza Surveillance Network produced by the Iowa Department of Public Health.

Influenza and Other Respiratory Virus Weekly Activity Report, November 15, 2008, Week 46

Weekly report of the Iowa Influenza Surveillance Network produced by the Iowa Department of Public Health.

Puheenvuoro SVUL:n liittokokouksessa 15.4.1939

Puhe

Aspectos oceanográficos en el invierno 2008: Crucero pelágico BIC Humboldt 0806-07

El Crucero BIC Humboldt 0806-07 se desarrolló del 3 de junio al 17 de julio 2008 en todo el mar peruano, como una evaluación hidroacústica del jurel (Trachurus murphyi) y la caballa (Scomber japonicus). Se registraron condiciones atípicas y grandes áreas de mezcla para la época. Las observaciones más importantes fueron: (1) las temperaturas fluctuaron entre 15,9 y 24,8 °C originando anomalías térmicas superficiales hasta de 2,6 °C en la zona norte, y anomalías próximas a lo normal en la zona sur; (2) la salinidad entre los 5 y 10°S mostró rezagos de la proyección de aguas ecuatoriales y tropicales durante el verano; (3) en la zona central se observó una marcada advección hacia la costa de aguas subtropicales superficiales entre Huarmey y Cerro Azul, formando una barrera para las aguas frías procedentes del sur; (4) estas aguas, al no proyectarse hacia el norte, giraron hacia el oeste originando mezclas y desplazamiento longitudinal de isotermas; (5) el afloramiento en general se mostró débil y restringido a la zona costera, principalmente entre San Juan y Ocoña; (6) en el nivel subsuperficial se registró una proyección de la Extensión Sur de la Corriente de Cromwell hasta el Callao; (7) en el sur, frente a Ocoña, se observó la presencia de Aguas Templadas de la Subantártica entre 25-70 mn y en la sección La Concordia fuera de las 250 mn.

Executive Order Number Fifteen, July 15, 2009

This Executive Order expects the State government to help more than 5,800 offenders released to Iowa communities each year, affecting public safety, public health, economic and community well-being and family relationships. Offenders re-entry initiatives involve collaborative partnerships amongst corrections, other agencies and the community.

Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers.

BACKGROUND: There is increasing evidence for the clinical relevance of mucosal healing (MH) as therapeutic treatment goal in inflammatory bowel disease (IBD). We aimed to investigate by which method gastroenterologists monitor IBD activity in daily practice. METHODS: A questionnaire was sent to all board-certified gastroenterologists in Switzerland to specifically address their strategy to monitor IBD between May 2009 and April 2010. RESULTS: The response rate was 57% (153/270). Fifty-two percent of gastroenterologists worked in private practice and 48% worked in hospitals. Seventy-eight percent judged clinical activity to be the most relevant criterion for monitoring IBD activity, 15% chose endoscopic severity, and 7% chose biomarkers. Seventy percent of gastroenterologists based their therapeutic decisions on clinical activity, 24% on endoscopic severity, and 6% on biomarkers. The following biomarkers were used for IBD activity monitoring: CRP, 94%; differential blood count, 78%; fecal calprotectin (FC), 74%; iron status, 63%; blood sedimentation rate, 3%; protein electrophoresis, 0.7%; fecal neutrophils, 0.7%; and vitamin B12, 0.7%. Gastroenterologists in hospitals and those with ≤ 10 years of professional experience used FC more frequently compared with colleagues in private practice (P=0.035) and those with > 10 years of experience (P<0.001). CONCLUSIONS: Clinical activity is judged to be more relevant for monitoring IBD activity and guiding therapeutic decisions than endoscopic severity and biomarkers. As such, the accumulating scientific evidence on the clinical impact of mucosal healing does not yet seem to influence the management of IBD in daily gastroenterologic practice.

Fiscal Update, February 15, 1999

The Fiscal Division newsletter, published weekly during session and periodically during the interim.

Fiscal Update, March 15, 1999

The Fiscal Division newsletter, published weekly during session and periodically during the interim.

Report on a special investigation of the Keokuk County Sheriff’s Office for the period July 1, 2006 through April 15, 2009

Report on a special investigation of the Keokuk County Sheriff’s Office for the period July 1, 2006 through April 15, 2009

Effects of an interleukin-15 antagonist on systemic and skeletal alterations in mice with DSS-induced colitis.

Inflammatory bowel diseases are commonly complicated by weight and bone loss. We hypothesized that IL-15, a pro-inflammatory cytokine expressed in colitis and an osteoclastogenic factor, could play a central role in systemic and skeletal complications of inflammatory bowel diseases. We evaluated the effects of an IL-15 antagonist, CRB-15, in mice with chronic colitis induced by oral 2% dextran sulfate sodium for 1 week, followed by another 1% for 2 weeks. During the last 2 weeks, mice were treated daily with CRB-15 or an IgG2a control antibody. Intestinal inflammation, disease severity, and bone parameters were evaluated at days 14 and 21. CRB-15 improved survival, early weight loss, and colitis clinical score, although colon damage and inflammation were prevented in only half the survivors. CRB-15 also delayed loss of femur bone mineral density and trabecular microarchitecture. Bone loss was characterized by decreased bone formation, but increased bone marrow osteoclast progenitors and osteoclast numbers on bone surfaces. CRB-15 prevented the suppression of osteoblastic markers of bone formation, and reduced osteoclast progenitors at day 14, but not later. However, by day 21, CRB-15 decreased tumor necrosis factor α and increased IL-10 expression in bone, paralleling a reduction of osteoclasts. These results delineate the role of IL-15 on the systemic and skeletal manifestations of chronic colitis and provide a proof-of-concept for future therapeutic developments.